---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011152"
form_type: "8-K"
ticker: "SCNX"
cik: "0001382574"
company_name: "Scienture Holdings, Inc."
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T08:36:58.563936+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Scienture receives FDA approval for Arbli (losartan oral suspension); launch planned Q3 2025

## Summary
- FDA approves SCN-102 as Arbli (losartan potassium oral suspension), first liquid ready-to-use losartan in US.
- Arbli indicated for hypertension (age >6), stroke risk reduction, diabetic nephropathy.
- US losartan market $292M annual sales, 68M prescriptions (IQVIA Dec 2024); global $1.5B.
- Commercial launch expected Q3 2025; product has 18-month shelf life at room temp.
- Consulting agreement with Draper Inc. for IR/business dev: 100k shares initial + 100k/mo.

## SEC filing metadata
- accession: 0001493152-25-011152
- form_type: 8-K
- ticker: SCNX
- cik: 0001382574
- company_name: Scienture Holdings, Inc.
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382574/000149315225011152/0001493152-25-011152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382574/000149315225011152/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011152
- JSON: https://secwatch.observer/filing/0001493152-25-011152.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011152.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.